The supplement and health industries are ever-evolving. Due to the constantly changing supplement landscape, it can be difficult to sort out genuine products from fads that do not offer any real value to consumers.
Recently, peptides have become a part of the supplement market. Peptides are essential to human life and are naturally occurring compounds that are present in every living cell. They are made of short chains of at least two amino acids and serve many different biological purposes.
Unlike many other supplements, peptides like ARA-290 can offer patients an affordable alternative to manage pain, improve symptoms, and promote healing.
What is ARA-290?
ARA-290 is a peptide that is derived from erythropoietin (EPO). EPO has been utilized for decades because of its ability to stimulate red blood cell production within bone marrow. It can also alter a patient’s blood pressure, promote cell survival, and create a neuroprotective effect.
While ARA-290 does not stimulate red blood cell production, it does offer pain-relieving and neuroprotective effects. It also has the potential to stimulate wound repair in patients with chronic diabetes, but this property is still being researched.
The full scope of ARA-290s benefits is still being researched. However, it has the potential to decrease the user’s inflammatory pathways through a process known as paracrine signaling. It has also been linked to reduced HbA1c and improved cholesterol numbers. Studies that have produced these results are still in the trial stages.
Perhaps the most appealing possibility for ARA-290 is that it may have the ability to reduce neuropathic symptoms and stimulate natural wound repair processes.
This peptide serves as an exciting treatment option for patients that are dealing with chronic neuropathic pain and diabetes-related ailments. It can also be safely paired with other peptides like BPC-157, which has healing properties.
Sarcoidosis is a condition characterized by the presence of tiny clusters of inflammatory cells in various parts of the body. Although most commonly observed in the lungs or lymph nodes, sarcoidosis can also affect other organs in the body, including the eyes, skin, and heart.
One of the most common clinical manifestations associated with sarcoidosis is a dysfunction of small nerve fibers that occurs in a patchy, non-length-dependent manner, a condition more commonly known as small fiber neuropathy (SFN). Symptoms of SFN include pins-and-needles, tingling, and numbness; in severe cases, SFN symptoms can include short sensations of shock-like or burning pain, allodynia, and loss of cutaneous sensation and autonomic function.
With the specific cause of sarcoidosis still unknown, and considering recent research demonstrating the prevalence of SFN being grossly underestimated and with no known cure for the condition, Heij et al. developed this randomized double-blind pilot study to examine the safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of SFN.
ARA 290 is a peptide that interacts with the innate repair receptor responsible for initiating cytoprotection, anti-inflammation, and healing. Considering that ARA 290 has been shown to reduce allodynia when tested in preclinical neuropathy models, Heij et. al. hypothesized that patients experiencing symptomatic SFN would benefit from treatment with ARA 290.
To test their hypothesis, the authors of this study enrolled 22 patients diagnosed with sarcoidosis and experiencing symptoms of SFN in either a group receiving intravenous dosing of ARA 290 or a placebo three times a week over the course of a four-week period.
At the conclusion of their study, Heij et al. observed that patients tolerated repeated intravenous infusions of ARA 290 without adverse events. The authors also observed a time-dependent, significant difference between ARA 290 and placebo groups. Specifically, ARA 290 appeared to improve autonomic and pain symptoms associated with SFN, including the severity of dry eyes, blurred vision, and muscle cramps and the severity and frequency of chest pain as assessed by the small fiber neuropathy screening list (SFNSL).
The authors concluded that their study was the first study to demonstrate that ARA 290 appears to be safe when administered repeatedly over a four-week period to sarcoidosis patients with symptoms of SFN with no abnormalities or drug-related adverse effects noted during and after dosing. ARA 290 also appeared to improve the severity and frequency of symptoms associated with SFN while also improving the quality of life and pain for these patients.
Heij et al. indicated that the primary limitations of this trial were the small sample size, patient variability of neuropathic involvement, and lack of skin biopsy or sudomotor testing evidence definitively establishing SFN. The study also demonstrated abnormalities in mechanoreception that prevented the observed reduction in the severity of symptoms as assessed by the SFNL from being fully attributed solely to the effects of ARA 290 on small-fiber function.
The observed reduction of SFN-associated symptoms combined with the acceptable safety demonstrated by frequent administrations of ARA 290 encourages a larger study to examine the potential effects of ARA 290 for sarcoidosis patients with symptoms of small fiber neuropathy.
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.